The CYP3A4*18 Allele, the Most Frequent Coding Variant in Asian Populations, Does Not Significantly Affect the Midazolam Disposition in Heterozygous Individuals

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Drug Metabolism And Disposition

• Publication date

  2007-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1124/dmd.107.016733PMID 17724065
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Systematic screening for polymorphisms in the CYP3A4 gene in the Chinese population.

  2006cited by this paper
• Human Pregnane X Receptor: Genetic Polymorphisms, Alternative mRNA Splice Variants, and Cytochrome P450 3A Metabolic Activity

  2006cited by this paper
• Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity

  2006cited by this paper
• CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population.

  2005cited by this paper
• Identification and functional characterization of novel CYP2J2 variants: G312R variant causes loss of enzyme catalytic activity

  2005cited by this paper
• Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus.

  2005cited by this paper
• Genotype‐phenotype Associations of Cytochrome P450 3A4 and 3A5 Polymorphism with Midazolam Clearance in Vivo

  2005cited by this paper
• Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests.

  2005cited by this paper
• Recombinant CYP3A4*17 Is Defective in Metabolizing the Hypertensive Drug Nifedipine, and the CYP3A4*17 Allele May Occur on the Same Chromosome as CYP3A5*3, Representing a New Putative Defective CYP3A Haplotype

  2005influential reference
• CYP3A5 GENETIC POLYMORPHISMS IN DIFFERENT ETHNIC POPULATIONS

  2005cited by this paper
• Experimental investigation of external explosion in the venting process.

  2005cited by this paper
• Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population

  2004influential reference
• Identification of a novel polymorphic enhancer of the human CYP3A4 gene.

  2004cited by this paper
• Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects

  2004cited by this paper
• Genetic variability in cytochrome P450 3A5 and in vivo cytochrome P450 3A activity: Some answers but still questions

  2004cited by this paper
• Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states

  2004cited by this paper
• The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients.

  2004cited by this paper
• GENETIC POLYMORPHISMS OF CYP3A5 GENES AND CONCENTRATION OF THE CYCLOSPORINE AND TACROLIMUS

  2004cited by this paper
• Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women.

  2003cited by this paper
• Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients12

  2003cited by this paper
• CYP3A4 and MDR1 Alleles in a Portuguese Population

  2003cited by this paper
• Increased transcriptional activity of the CYP3A4*1B promoter variant

  2003cited by this paper
• Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism.

  2003cited by this paper
• Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR‐1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus

  2003cited by this paper
• Association of the CYP3A4*1B 5´-Flanking Region Polymorphism With Cyclosporine Pharmacokinetics in Healthy Subjects

  2003cited by this paper
• CYP3A4*18: it is not rare allele in Japanese population.

  2003influential reference
• Does the CYP3A5*3 polymorphism affect in vivo drug elimination?

  2003cited by this paper
• CYP3A4 gene polymorphisms influence testosterone 6beta-hydroxylation.

  2002cited by this paper
• Common allelic variants of cytochrome P4503A4 and their prevalence in different populations.

  2002cited by this paper
• Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.

  2002cited by this paper
• Genetic contribution to variable human CYP3A-mediated metabolism.

  2002influential reference
• Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes.

  2002cited by this paper
• Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: an evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation.

  2002cited by this paper
• Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism.

  2002cited by this paper
• CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity

  2002cited by this paper
• Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

  2001influential reference
• Novel mutations of CYP3A4 in Chinese.

  2001influential reference
• Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos.

  2001influential reference
• Identification and functional characterization of eight CYP3A4 protein variants.

  2001influential reference
• CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity

  2000influential reference
• Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method.

  2000cited by this paper
• CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4*1B 5′‐promoter region polymorphism

  2000cited by this paper
• Frequency of cytochrome P450 3A4 variant genotype in transplant population and lack of association with cyclosporin clearance

  2000cited by this paper
• Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent.

  2000cited by this paper
• Interrelationship Between Substrates and Inhibitors of Human CYP3A and P-Glycoprotein

  1999cited by this paper
• Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region.

  1999cited by this paper
• Cytochrome P-450 3A4: regulation and role in drug metabolism.

  1999cited by this paper
• In vitro and in vivo drug interactions involving human CYP3A.

  1998cited by this paper
• Quantification of 3‐month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam

  1998cited by this paper
• Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

  1994cited by this paper
• Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences.

  1992cited by this paper
• Fetus-specific expression of a form of cytochrome P-450 in human livers.

  1990cited by this paper
• Site-directed mutagenesis by overlap extension using the polymerase chain reaction.

  1989cited by this paper
• THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. II. SOLUBILIZATION, PURIFICATION, AND PROPERTIES.

  1964cited by this paper
• THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE.

  1964cited by this paper

• Association of NR1I2 Polymorphism with Midazolam Clearance in Mechanically Ventilated ICU Patients: A Population Pharmacokinetic and Pharmacogenetic Study

  2025cites this paper
• Efficacy and safety of perampanel as first adjunctive therapy in patients with focal‐onset seizures or generalized tonic‐clonic seizures in four post‐marketing studies across regions

  2025cites this paper
• Effects of CYP3A4 Variants on Methadone Metabolism In Vitro.

  2024cites this paper
• The influence of drug-induced metabolic enzyme activity inhibition and CYP3A4 gene polymorphism on aumolertinib metabolism

  2024cites this paper
• Metabolism of the antipsychotic drug olanzapine by CYP3A43

  2022cites this paper
• Significance of ethnic factors in immunosuppressive therapy management after organ transplantation.

  2020cites this paper
• Pharmacokinetics, Safety, and Tolerability of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Healthy Chinese Subjects.

  2020cites this paper
• Enzymatic Activities of CYP3A4 Allelic Variants on Quinine 3-Hydroxylation In Vitro

  2019cites this paper
• Effects of CYP2C19 and CYP3A5 genetic polymorphisms on the pharmacokinetics of cilostazol and its active metabolites

  2018cites this paper
• Systematic screening for CYP3A4 genetic polymorphisms in a Han Chinese population.

  2017cites this paper
• Impact of CYP3A4*18 and CYP3A5*3 Polymorphisms on Imatinib Mesylate Response Among Chronic Myeloid Leukemia Patients in Malaysia

  2016influential citation
• Role of OPRM 1 , ABCB 1 and CYP 3 A genetic polymorphisms on sufentanil treatment of postoperative cancer patients in China

  2016cites this paper
• Opioid pharmacogenetics in anesthesia and pain management

  2015cites this paper
• Clinical Pharmacology of Frequently Used Intravenous Drugs During Bariatric Surgery in Adolescents.

  2015cites this paper
• Drug‐induced liver injury in a chronic hepatitis C patient treated by peginterferon, ribavirin and simeprevir

  2015cites this paper
• AUTOINDUCTION PROPERTIES OF RIFAMPICIN ON JAVANESE TUBERCULOSIS WITH VARIANT TYPE CYP3A4*1G

  2015cites this paper
• The impact of genetic variation on sensitivity to opioid analgesics in patients with postoperative pain: a systematic review and meta-analysis.

  2015cites this paper
• Slow carbamazepine clearance in a nonadherent Malay woman with epilepsy and thyrotoxicosis.

  2014cites this paper
• Genetic polymorphisms of CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 in Vietnamese-Koreans

  2014influential citation
• The effect of CYP2C19 genotype on the time course of platelet aggregation inhibition after clopidogrel administration

  2014cites this paper
• Impact of CYP3A and ABCB1 polymorphisms on the pharmacokinetics and pharmacodynamics of fentanyl.

  2013cites this paper
• Screening of Genetic Polymorphisms of CYP3A4 and CYP3A5 Genes

  2013cites this paper
• Effects of genetic polymorphisms of OPRM1, ABCB1, CYP3A4/5 on postoperative fentanyl consumption in Korean gynecologic patients.

  2013cites this paper
• Screening of Genetic Polymorphisms of CYP 3 A 4 and CYP 3 A 5 Genes

  2013cites this paper
• Effect of CYP2C19 Genetic Polymorphism on Pharmacokinetics and Pharmacodynamics and Pharmacodynamics of a New Proton Pump Inhibitor, Ilaprazole

  2012cites this paper
• Engineering of Human CYP3A Enzymes by Combination of Activating Polymorphic Variants

  2012cites this paper
• Pharmacokinetic effect of voriconazole on cyclosporine in the treatment of aspergillosis after renal transplantation.

  2012cites this paper
• Identification of human cytochrome P450 enzymes involved in the metabolism of a novel к‐opioid receptor agonist, nalfurafine hydrochloride

  2012cites this paper
• Cytochrome P450 3A4 genetic polymorphisms and post‐operative fentanyl requirements

  2012cites this paper
• Pharmacokinetics of felodipine extended-release tablets in healthy Taiwanese subjects: a retrospective review.

  2011cites this paper
• Analysis of CYP3A4 genetic polymorphisms in Han Chinese

  2011cites this paper
• Pharmacokinetics of felodipine extended-release tablets in healthy Taiwanese subjects: a retrospective review

  2011cites this paper
• A haplotype of CYP2C9 associated with warfarin sensitivity in mechanical heart valve replacement patients.

  2010cites this paper
• CYP 3 A 4 * 16 and CYP 3 A 4 * 18 Alleles Found in East Asians Exhibit Differential Catalytic Activities for Seven CYP 3 A 4 Substrate Drugs

  2010influential citation
• Human variation in CYP-specific chlorpyrifos metabolism.

  2010cites this paper
• CYP3A4*16 and CYP3A4*18 Alleles Found in East Asians Exhibit Differential Catalytic Activities for Seven CYP3A4 Substrate Drugs

  2010influential citation
• Human Hepatic Expression of CYP2B6: Developmental Pattern and In Vitro Bioactivation of Chlorpyrifos.

  2009influential citation
• Functional characterization of CYP3A4.16: Catalytic activities toward midazolam and carbamazepine

  2009influential citation
• Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India

  2009cites this paper
• Pharmacogenetics of anesthetics

  2008cites this paper
• An NH2-terminal truncated cytochrome P450 CYP3A4 showing catalytic activity is present in the cytoplasm of human liver cells

  2008cites this paper